派格生物医药-B(02565):CR059相关研究摘要获美国糖尿病协会2026年科学年会接收并入选最新突破性摘要

智通财经

Apr 02

智通财经APP讯，派格生物医药-B(02565)发布公告，集团自主研发的创新候选产品CR059 相关研究摘要已获美国糖尿病协会(American Diabetes Association, ADA)2026年科学年会接收，并入选Late Breaking Abstract(最新突破性摘要)，将以海报形式(poster presentation)展示。相关摘要题为：CR059, a Once-Monthly circRNA-Encoded GLP-1 Analogue, Demonstrates Durable Glycemic Control in T2D Rhesus Monkeys。

CR059为集团自主研发的创新候选产品。根据相关研究结果，CR059展现出显著减重效果、突出的降糖表现及长期表达特征，并显示出作为长效代谢疾病治疗方案的开发潜力。摘要亦显示，CR059基于circRNA-LNP技术平台，有望实现按月给药，甚至延长至季度给药，并支持持续表达及长效代谢控制。

美国糖尿病协会科学年会是糖尿病及代谢疾病领域具有国际影响力的学术会议之一。董事会认为，本次CR059相关研究摘要获接收并入选Late Breaking Abstract (最新突破性摘要)，体现了国际学术界对集团在代谢疾病创新研发领域最新进展的关注，有助于提升CR059项目的国际学术影响力，并增强市场对集团创新研发能力及技术平台价值的认知。

根据会议安排，上述研究摘要将于ADA 2026年科学年会期间以海报形式展示。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2624503214"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2624503214\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2624503214?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-04-02 19:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624503214","market":"sh","top_or_hot":-1,"title":"派格生物医药-B(02565):CR059相关研究摘要获美国糖尿病协会2026年科学年会接收并入选最新突破性摘要","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/02565\">派格生物医药-B</a>(02565)发布公告，集团自主研发的创新候选产品CR059 相关研究摘要已获美国糖尿病协会(American Diabetes Association, ADA)2026年科学年会接收，并入选Late Breaking Abstract(最新突破性摘要)，将以海报形式(poster presentation)展示。相关摘要题为：CR059, a Once-Monthly circRNA-Encoded GLP-1 Analogue, Demonstrates Durable Glycemic Control in T2D Rhesus Monkeys。</p><p>CR059为集团自主研发的创新候选产品。根据相关研究结果，CR059展现出显著减重效果、突出的降糖表现及长期表达特征，并显示出作为长效代谢疾病治疗方案的开发潜力。摘要亦显示，CR059基于circRNA-LNP技术平台，有望实现按月给药，甚至延长至季度给药，并支持持续表达及长效代谢控制。</p><p>美国糖尿病协会科学年会是糖尿病及代谢疾病领域具有国际影响力的学术会议之一。董事会认为，本次CR059相关研究摘要获接收并入选Late Breaking Abstract (最新突破性摘要)，体现了国际学术界对集团在代谢疾病创新研发领域最新进展的关注，有助于提升CR059项目的国际学术影响力，并增强市场对集团创新研发能力及技术平台价值的认知。</p><p>根据会议安排，上述研究摘要将于ADA 2026年科学年会期间以海报形式展示。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>派格生物医药-B(02565):CR059相关研究摘要获美国糖尿病协会2026年科学年会接收并入选最新突破性摘要</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n派格生物医药-B(02565):CR059相关研究摘要获美国糖尿病协会2026年科学年会接收并入选最新突破性摘要\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-02 19:15 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1424738.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，派格生物医药-B(02565)发布公告，集团自主研发的创新候选产品CR059 相关研究摘要已获美国糖尿病协会(American Diabetes Association, ADA)2026年科学年会接收，并入选Late Breaking Abstract(最新突破性摘要)，将以海报形式(poster presentation)展示。相关摘要题为：CR059, a Once-...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1424738.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"161726","symbol_name":"生物医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1424738.html","article_id":"2624503214","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624503214","pubTimestamp":1775128554,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，派格生物医药-B 发布公告，集团自主研发的创新候选产品CR059 相关研究摘要已获美国糖尿病协会2026年科学年会接收，并入选Late Breaking Abstract，将以海报形式展示。根据相关研究结果，CR059展现出显著减重效果、突出的降糖表现及长期表达特征，并显示出作为长效代谢疾病治疗方案的开发潜力。美国糖尿病协会科学年会是糖尿病及代谢疾病领域具有国际影响力的学术会议之一。根据会议安排，上述研究摘要将于ADA 2026年科学年会期间以海报形式展示。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"161726":"生物医药","399441":"生物医药","XBI":"SPDR S&P Biotech ETF","02565":"派格生物医药-B","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK4581":"高盛持仓"},"translate_title":"The research abstract related to Paige Biomedical-B (02565): CR059 was accepted by the American Diabetes Association 2026 Annual Scientific Meeting and selected as the latest breakthrough abstract","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161726":1.5,"399441":1.5,"02565":1.5,"XBI":1.5},"content_text":"智通财经APP讯，派格生物医药-B(02565)发布公告，集团自主研发的创新候选产品CR059 相关研究摘要已获美国糖尿病协会(American Diabetes Association, ADA)2026年科学年会接收，并入选Late Breaking Abstract(最新突破性摘要)，将以海报形式(poster presentation)展示。相关摘要题为：CR059, a Once-Monthly circRNA-Encoded GLP-1 Analogue, Demonstrates Durable Glycemic Control in T2D Rhesus Monkeys。CR059为集团自主研发的创新候选产品。根据相关研究结果，CR059展现出显著减重效果、突出的降糖表现及长期表达特征，并显示出作为长效代谢疾病治疗方案的开发潜力。摘要亦显示，CR059基于circRNA-LNP技术平台，有望实现按月给药，甚至延长至季度给药，并支持持续表达及长效代谢控制。美国糖尿病协会科学年会是糖尿病及代谢疾病领域具有国际影响力的学术会议之一。董事会认为，本次CR059相关研究摘要获接收并入选Late Breaking Abstract (最新突破性摘要)，体现了国际学术界对集团在代谢疾病创新研发领域最新进展的关注，有助于提升CR059项目的国际学术影响力，并增强市场对集团创新研发能力及技术平台价值的认知。根据会议安排，上述研究摘要将于ADA 2026年科学年会期间以海报形式展示。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}